Adial Pharmaceuticals (ADIL) Competitors $1.07 +0.02 (+1.90%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ADIL vs. DARE, DRRX, LGVN, LPCN, NAII, LVTX, PLUR, ENLV, LSB, and EQShould you be buying Adial Pharmaceuticals stock or one of its competitors? The main competitors of Adial Pharmaceuticals include Daré Bioscience (DARE), DURECT (DRRX), Longeveron (LGVN), Lipocine (LPCN), Natural Alternatives International (NAII), LAVA Therapeutics (LVTX), Pluri (PLUR), Enlivex Therapeutics (ENLV), Lakeshore Biopharma (LSB), and Equillium (EQ). These companies are all part of the "pharmaceutical products" industry. Adial Pharmaceuticals vs. Daré Bioscience DURECT Longeveron Lipocine Natural Alternatives International LAVA Therapeutics Pluri Enlivex Therapeutics Lakeshore Biopharma Equillium Adial Pharmaceuticals (NASDAQ:ADIL) and Daré Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, community ranking, institutional ownership and earnings. Do analysts prefer ADIL or DARE? Adial Pharmaceuticals presently has a consensus price target of $8.00, indicating a potential upside of 647.66%. Daré Bioscience has a consensus price target of $24.00, indicating a potential upside of 785.61%. Given Daré Bioscience's higher possible upside, analysts clearly believe Daré Bioscience is more favorable than Adial Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Daré Bioscience 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media prefer ADIL or DARE? In the previous week, Daré Bioscience had 1 more articles in the media than Adial Pharmaceuticals. MarketBeat recorded 3 mentions for Daré Bioscience and 2 mentions for Adial Pharmaceuticals. Adial Pharmaceuticals' average media sentiment score of 0.82 beat Daré Bioscience's score of 0.01 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Daré Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is ADIL or DARE more profitable? Adial Pharmaceuticals has a net margin of 0.00% compared to Daré Bioscience's net margin of -191.65%. Daré Bioscience's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Adial PharmaceuticalsN/A -168.25% -148.46% Daré Bioscience -191.65%N/A -18.98% Do institutionals & insiders have more ownership in ADIL or DARE? 16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of Daré Bioscience shares are owned by institutional investors. 5.2% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 4.0% of Daré Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has preferable valuation and earnings, ADIL or DARE? Adial Pharmaceuticals has higher earnings, but lower revenue than Daré Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdial PharmaceuticalsN/AN/A-$5.12MN/AN/ADaré Bioscience$1.88M12.53-$30.16M-$0.59-4.59 Does the MarketBeat Community prefer ADIL or DARE? Daré Bioscience received 247 more outperform votes than Adial Pharmaceuticals when rated by MarketBeat users. Likewise, 73.31% of users gave Daré Bioscience an outperform vote while only 58.51% of users gave Adial Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAdial PharmaceuticalsOutperform Votes11058.51% Underperform Votes7841.49% Daré BioscienceOutperform Votes35773.31% Underperform Votes13026.69% Which has more risk & volatility, ADIL or DARE? Adial Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500. Comparatively, Daré Bioscience has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. SummaryAdial Pharmaceuticals and Daré Bioscience tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Adial Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADIL vs. The Competition Export to ExcelMetricAdial PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.73M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5589.7417.16Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.86Price / Book0.435.094.784.78Net Income-$5.12M$151.83M$120.31M$225.60M7 Day Performance-1.83%-2.14%-1.92%-1.23%1 Month Performance5.94%-4.56%13.65%0.46%1 Year Performance-41.85%8.87%28.34%15.24% Adial Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADILAdial Pharmaceuticals3.3523 of 5 stars$1.07+1.9%$8.00+647.7%-41.8%$6.73MN/A0.0020News CoveragePositive NewsDAREDaré Bioscience1.5891 of 5 stars$3.18flat$24.00+654.7%-28.4%$27.67M$1.88M-5.3930Analyst ForecastGap DownDRRXDURECT2.6267 of 5 stars$0.89+18.7%$5.00+461.8%+83.5%$27.63M$8.59M-1.3980Analyst ForecastNews CoverageLGVNLongeveron3.4375 of 5 stars$1.83-1.6%$8.67+373.6%-86.8%$27.15M$1.89M-0.3023LPCNLipocine1.5291 of 5 stars$4.97-1.0%$10.00+101.2%+66.5%$26.58M$7.92M-6.6110News CoverageNAIINatural Alternatives InternationalN/A$4.21-2.1%N/A-35.9%$26.10M$112.98M-2.99290Analyst ForecastLVTXLAVA Therapeutics3.0636 of 5 stars$1.02-8.2%$4.67+358.0%-31.8%$25.83M$7.35M-1.0860Analyst ForecastGap DownPLURPluri0.4276 of 5 stars$4.62-2.1%N/A+5.9%$25.69M$330,000.000.00150News CoveragePositive NewsENLVEnlivex Therapeutics2.321 of 5 stars$1.18-1.7%$9.50+705.1%-45.6%$25.26MN/A0.0070LSBLakeshore Biopharma0.4967 of 5 stars$2.65+6.4%N/AN/A$24.67M$80.82M0.00773News CoverageGap UpEQEquillium2.7452 of 5 stars$0.68-3.5%$5.00+635.3%-7.7%$24.09M$45.91M-5.0440Gap Down Related Companies and Tools Related Companies Daré Bioscience Alternatives DURECT Alternatives Longeveron Alternatives Lipocine Alternatives Natural Alternatives International Alternatives LAVA Therapeutics Alternatives Pluri Alternatives Enlivex Therapeutics Alternatives Lakeshore Biopharma Alternatives Equillium Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADIL) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredMUST SEE: The most important video in the world right now?If you have a significant amount of money in the stock market right now — or if you're sitting on the sideline...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
